Home ›
Breast Cancer Trials ›
NCT05716516
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
Determine whether subjects harboring ESR1-mutant/amplified breast cancer have a higher rate of clinical benefit from 17b-estradiol therapy than subjects with ESR1-wild-type breast cancer
Trial Details
NCT ID NCT05716516
Phase PHASE2
Sponsor Dartmouth-Hitchcock Medical Center
Status RECRUITING
Cancer Type Breast Cancer
Interventions
Locations (sample) Lebanon, New Hampshire, United States|43.64229,-72.25176
Key Eligibility Criteria
Post-menopausal women with ER+ breast cancer. Metastatic or locoregional recurrence not amenable to treatment with curative Received ≥1 prior line of endocrine-based therapy (e.g., including tamoxifen, aromatase inhibitors, fulvestrant, or combinations) in the advanced/m…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Breast Cancer Trials on Trialify →